TMEM165

Across TCGA pan-cancer cohorts, TMEM165 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM165 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM165 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM165 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, CCRCC, and LSCC are the cancer types where TMEM165 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.873	0.673	.001	37	view →
CCRCC	OS	Median	All	0.647	1.000	.005	31	view →
LSCC	OS	Quartile	All	0.637	0.887	.012	16	view →
PDAC	DFS	Tertile	II,III,IV	0.789	0.607	.032	4	view →
LUAD	DFS	Median	All	0.675	0.955	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM165–HNSC (DFS)

Open the HNSC breakdown →